Grifols SA
MAD:GRF

Watchlist Manager
Grifols SA Logo
Grifols SA
MAD:GRF
Watchlist
Price: 9.24 EUR 0.41%
Market Cap: 6.3B EUR
Have any thoughts about
Grifols SA?
Write Note

Gross Margin
Grifols SA

38.8%
Current
38%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
38.8%
=
Gross Profit
2.7B
/
Revenue
7B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
ES
Grifols SA
MAD:GRF
6.3B EUR
39%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
315.2B USD
67%
US
Amgen Inc
NASDAQ:AMGN
141.9B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
135.7B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
36B EUR
89%
Country ES
Market Cap 6.3B EUR
Gross Margin
39%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 315.2B USD
Gross Margin
67%
Country US
Market Cap 141.9B USD
Gross Margin
60%
Country US
Market Cap 116.4B USD
Gross Margin
78%
Country US
Market Cap 104.5B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 135.7B AUD
Gross Margin
52%
Country US
Market Cap 78.7B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36B EUR
Gross Margin
89%
No Stocks Found

Grifols SA
Glance View

Market Cap
6.3B EUR
Industry
Biotechnology

Grifols SA, a global healthcare giant based in Barcelona, Spain, has carved its niche in the world through its pioneering work with plasma-derived medicines. Founded in 1940, the company has grown from a small family business into one of the world leaders in the production and development of biopharmaceuticals, particularly those derived from human plasma. Grifols operates a robust network of plasma donation centers, primarily in the United States, where it sources its primary raw material. The company's meticulous process involves collecting plasma from donors, which is then transported to sophisticated manufacturing facilities. Here, this vital fluid is fractionated into various components used to create life-saving treatments. These treatments address a spectrum of conditions, including hemophilia, immune deficiencies, and neurological issues, highlighting Grifols' integral role in advancing healthcare solutions. Grifols' business model is astutely designed to capitalize on the high demand for plasma-derived therapies, ensuring a steady stream of revenue. By vertically integrating its operations—from plasma collection through to product distribution—Grifols maintains stringent quality control and operational efficiency, driving down costs and enhancing margins. The company's segmentation includes Bioscience, which focuses on plasma-derived therapies; Diagnostic, which involves manufacturing tools and reagents for clinical analysis; and Hospital, which manages pharmacy and healthcare logistics products. Furthermore, the company has ventured into bio supplies, supplying biological materials for non-therapeutic use to life-science research. With a deep commitment to innovation and strategic acquisitions, Grifols stays ahead in the competitive biopharmaceutical landscape while fostering a direct link between donor generosity and patient needs, ensuring that its growth story has a profound impact on global health.

GRF Intrinsic Value
24.04 EUR
Undervaluation 62%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
38.8%
=
Gross Profit
2.7B
/
Revenue
7B
What is the Gross Margin of Grifols SA?

Based on Grifols SA's most recent financial statements, the company has Gross Margin of 38.8%.